{"id":1464,"date":"2023-08-25T11:04:15","date_gmt":"2023-08-25T15:04:15","guid":{"rendered":"https:\/\/9bio.ca\/?page_id=1464"},"modified":"2026-06-01T17:57:44","modified_gmt":"2026-06-01T21:57:44","slug":"pipeline","status":"publish","type":"page","link":"https:\/\/9biotx.com\/fr\/pipeline\/","title":{"rendered":"Pipeline"},"content":{"rendered":"<style>.kb-row-layout-id1464_63f508-80 > .kt-row-column-wrap{align-content:start;}:where(.kb-row-layout-id1464_63f508-80 > .kt-row-column-wrap) > .wp-block-kadence-column{justify-content:start;}.kb-row-layout-id1464_63f508-80 > .kt-row-column-wrap{column-gap:var(--global-kb-gap-md, 2rem);row-gap:var(--global-kb-gap-md, 2rem);max-width:700px;margin-left:auto;margin-right:auto;padding-top:var(--global-kb-spacing-5xl, 10rem);padding-bottom:var(--global-kb-spacing-xxl, 5rem);grid-template-columns:minmax(0, 1fr);}.kb-row-layout-id1464_63f508-80{background-image:url('http:\/\/9bio.ca\/wp-content\/uploads\/2023\/08\/9bio-background-image-compressed.jpg');background-size:cover;background-position:51% 70%;background-attachment:scroll;background-repeat:no-repeat;}.kb-row-layout-id1464_63f508-80 > .kt-row-layout-overlay{opacity:0.75;background-color:var(--global-palette1, #3182CE);mix-blend-mode:normal;}@media all and (max-width: 1024px){.kb-row-layout-id1464_63f508-80 > .kt-row-column-wrap{grid-template-columns:minmax(0, 1fr);}}@media all and (max-width: 767px){.kb-row-layout-id1464_63f508-80 > .kt-row-column-wrap{grid-template-columns:minmax(0, 1fr);}}<\/style><div class=\"kb-row-layout-wrap kb-row-layout-id1464_63f508-80 alignnone kt-row-has-bg wp-block-kadence-rowlayout\"><div class=\"kt-row-layout-overlay kt-row-overlay-normal\"><\/div><div class=\"kt-row-column-wrap kt-has-1-columns kt-row-layout-equal kt-tab-layout-inherit kt-mobile-layout-row kt-row-valign-top\">\n<style>.kadence-column1464_eb7764-3e > .kt-inside-inner-col,.kadence-column1464_eb7764-3e > .kt-inside-inner-col:before{border-top-left-radius:0px;border-top-right-radius:0px;border-bottom-right-radius:0px;border-bottom-left-radius:0px;}.kadence-column1464_eb7764-3e > .kt-inside-inner-col{column-gap:var(--global-kb-gap-sm, 1rem);}.kadence-column1464_eb7764-3e > .kt-inside-inner-col{flex-direction:column;}.kadence-column1464_eb7764-3e > .kt-inside-inner-col > .aligncenter{width:100%;}.kadence-column1464_eb7764-3e > .kt-inside-inner-col:before{opacity:0.3;}.kadence-column1464_eb7764-3e{position:relative;}@media all and (max-width: 1024px){.kadence-column1464_eb7764-3e > .kt-inside-inner-col{flex-direction:column;justify-content:center;}}@media all and (max-width: 767px){.kadence-column1464_eb7764-3e > .kt-inside-inner-col{flex-direction:column;justify-content:center;}}<\/style>\n<div class=\"wp-block-kadence-column kadence-column1464_eb7764-3e\"><div class=\"kt-inside-inner-col\"><style>.wp-block-kadence-advancedheading.kt-adv-heading1464_7e98f3-00, .wp-block-kadence-advancedheading.kt-adv-heading1464_7e98f3-00[data-kb-block=\"kb-adv-heading1464_7e98f3-00\"]{text-align:center;font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading1464_7e98f3-00 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading1464_7e98f3-00[data-kb-block=\"kb-adv-heading1464_7e98f3-00\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}.wp-block-kadence-advancedheading.kt-adv-heading1464_7e98f3-00 img.kb-inline-image, .wp-block-kadence-advancedheading.kt-adv-heading1464_7e98f3-00[data-kb-block=\"kb-adv-heading1464_7e98f3-00\"] img.kb-inline-image{width:150px;vertical-align:baseline;}<\/style>\n<h2 class=\"kt-adv-heading1464_7e98f3-00 wp-block-kadence-advancedheading has-theme-palette-9-color has-text-color\" data-kb-block=\"kb-adv-heading1464_7e98f3-00\">Pipeline<\/h2>\n\n\n\n<p class=\"has-text-align-center has-theme-palette-9-color has-text-color wp-block-paragraph\"><ins>Conditionally active precision oncology therapeutics<\/ins><\/p>\n<\/div><\/div>\n\n<\/div><\/div>\n\n<style>.kb-row-layout-wrap.wp-block-kadence-rowlayout.kb-row-layout-id1464_0a18db-1f{margin-top:0px;margin-bottom:0px;}.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap{align-content:center;}:where(.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap) > .wp-block-kadence-column{justify-content:center;}.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap{column-gap:var(--global-kb-gap-none, 0rem );row-gap:var(--global-kb-gap-md, 2rem);max-width:var( --global-content-width, 1200px );padding-left:var(--global-content-edge-padding);padding-right:var(--global-content-edge-padding);padding-top:var(--global-kb-spacing-lg, 3rem);padding-bottom:60px;grid-template-columns:minmax(0, 1fr);}.kb-row-layout-id1464_0a18db-1f > .kt-row-layout-overlay{opacity:0.30;}@media all and (max-width: 1024px){.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap{column-gap:var(--global-kb-gap-none, 0rem );row-gap:var(--global-kb-gap-none, 0rem );padding-top:var(--global-kb-spacing-xl, 4rem);grid-template-columns:minmax(0, 1fr);}}@media all and (max-width: 767px){.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap{row-gap:var(--global-kb-gap-md, 2rem);padding-top:var(--global-kb-spacing-xl, 4rem);padding-right:0px;padding-left:0px;grid-template-columns:minmax(0, 1fr);}.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap > .wp-block-kadence-column:nth-child(1 of *:not(style)){order:1;}.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap > .wp-block-kadence-column:nth-child(2 of *:not(style)){order:11;}.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap > .wp-block-kadence-column:nth-child(3 of *:not(style)){order:21;}.kb-row-layout-id1464_0a18db-1f > .kt-row-column-wrap > .wp-block-kadence-column:nth-child(4 of *:not(style)){order:31;}}<\/style><div class=\"kb-row-layout-wrap kb-row-layout-id1464_0a18db-1f alignfull has-theme-palette7-background-color kt-row-has-bg wp-block-kadence-rowlayout\" id=\"pipeline\"><div class=\"kt-row-column-wrap kt-has-1-columns kt-row-layout-equal kt-tab-layout-inherit kt-mobile-layout-row kt-row-valign-middle kt-inner-column-height-full kb-theme-content-width\">\n<style>.kadence-column1464_f52b0d-da > .kt-inside-inner-col{display:flex;}.kadence-column1464_f52b0d-da > .kt-inside-inner-col{padding-top:0px;padding-right:var(--global-kb-spacing-3xl, 6.5rem);padding-bottom:0px;padding-left:0px;}.kadence-column1464_f52b0d-da > .kt-inside-inner-col,.kadence-column1464_f52b0d-da > .kt-inside-inner-col:before{border-top-left-radius:0px;border-top-right-radius:0px;border-bottom-right-radius:0px;border-bottom-left-radius:0px;}.kadence-column1464_f52b0d-da > .kt-inside-inner-col{column-gap:0px;}.kadence-column1464_f52b0d-da > .kt-inside-inner-col{flex-direction:column;justify-content:flex-start;}.kadence-column1464_f52b0d-da > .kt-inside-inner-col > .aligncenter{width:100%;}.kt-row-column-wrap > .kadence-column1464_f52b0d-da{align-self:flex-start;}.kt-inner-column-height-full:not(.kt-has-1-columns) > .wp-block-kadence-column.kadence-column1464_f52b0d-da{align-self:auto;}.kt-inner-column-height-full:not(.kt-has-1-columns) > .wp-block-kadence-column.kadence-column1464_f52b0d-da > .kt-inside-inner-col{flex-direction:column;justify-content:flex-start;}.kadence-column1464_f52b0d-da > .kt-inside-inner-col:before{opacity:0.3;}.kadence-column1464_f52b0d-da{position:relative;}@media all and (max-width: 1024px){.kadence-column1464_f52b0d-da > .kt-inside-inner-col{padding-right:var(--global-kb-spacing-md, 2rem);padding-bottom:var(--global-kb-spacing-md, 2rem);flex-direction:column;justify-content:flex-start;}}@media all and (max-width: 1024px){.kt-row-column-wrap > .kadence-column1464_f52b0d-da{align-self:flex-start;}}@media all and (max-width: 1024px){.kt-inner-column-height-full:not(.kt-has-1-columns) > .wp-block-kadence-column.kadence-column1464_f52b0d-da{align-self:auto;}}@media all and (max-width: 1024px){.kt-inner-column-height-full:not(.kt-has-1-columns) > .wp-block-kadence-column.kadence-column1464_f52b0d-da > .kt-inside-inner-col{flex-direction:column;justify-content:flex-start;}}@media all and (max-width: 767px){.kadence-column1464_f52b0d-da > .kt-inside-inner-col{padding-right:var(--global-kb-spacing-sm, 1.5rem);padding-left:var(--global-kb-spacing-md, 2rem);flex-direction:column;justify-content:flex-start;}.kt-row-column-wrap > .kadence-column1464_f52b0d-da{align-self:flex-start;}.kt-inner-column-height-full:not(.kt-has-1-columns) > .wp-block-kadence-column.kadence-column1464_f52b0d-da{align-self:auto;}.kt-inner-column-height-full:not(.kt-has-1-columns) > .wp-block-kadence-column.kadence-column1464_f52b0d-da > .kt-inside-inner-col{flex-direction:column;justify-content:flex-start;}}<\/style>\n<div class=\"wp-block-kadence-column kadence-column1464_f52b0d-da kb-section-dir-vertical kb-section-md-dir-vertical inner-column-2\" data-aos=\"fade-up\" data-aos-duration=\"2000\" data-aos-delay=\"300\"><div class=\"kt-inside-inner-col\"><style>.kadence-column1464_5a5a7f-5c > .kt-inside-inner-col,.kadence-column1464_5a5a7f-5c > .kt-inside-inner-col:before{border-top-left-radius:0px;border-top-right-radius:0px;border-bottom-right-radius:0px;border-bottom-left-radius:0px;}.kadence-column1464_5a5a7f-5c > .kt-inside-inner-col{column-gap:var(--global-kb-gap-sm, 1rem);}.kadence-column1464_5a5a7f-5c > .kt-inside-inner-col{flex-direction:column;}.kadence-column1464_5a5a7f-5c > .kt-inside-inner-col > .aligncenter{width:100%;}.kadence-column1464_5a5a7f-5c > .kt-inside-inner-col:before{opacity:0.3;}.kadence-column1464_5a5a7f-5c{position:relative;}@media all and (max-width: 1024px){.kadence-column1464_5a5a7f-5c > .kt-inside-inner-col{flex-direction:column;justify-content:center;}}@media all and (max-width: 767px){.kadence-column1464_5a5a7f-5c > .kt-inside-inner-col{flex-direction:column;justify-content:center;}}<\/style>\n<div class=\"wp-block-kadence-column kadence-column1464_5a5a7f-5c\"><div class=\"kt-inside-inner-col\">\n<p class=\"wp-block-paragraph\">Our pipeline directly&nbsp;validates&nbsp;the capabilities of our computational platform and is guided by two core&nbsp;objectives.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">First, we use our platform to reduce off-tumor target engagement and develop antibody-drug conjugates (ADCs) for tumor antigens that have historically been difficult to drug due to expression in healthy tissues. This allows us to pursue cancers where treatment options&nbsp;remain&nbsp;limited&nbsp;and survival rates are still unacceptably low.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Second, by improving specificity, we aim to enhance the bioavailability and tolerability of our therapeutics, supporting more effective treatments for patients who may be unable to tolerate existing therapies or are forced to&nbsp;discontinue&nbsp;treatment due to complications.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Through this work, we aim to advance clinically meaningful, broadly applicable, and more inclusive cancer therapies \u2013 offering renewed hope to patients and their families.<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n<\/div><\/div>\n\n<style>.kb-row-layout-id1464_45d497-9e > .kt-row-column-wrap{align-content:start;}:where(.kb-row-layout-id1464_45d497-9e > .kt-row-column-wrap) > .wp-block-kadence-column{justify-content:start;}.kb-row-layout-id1464_45d497-9e > .kt-row-column-wrap{column-gap:var(--global-kb-gap-md, 2rem);row-gap:var(--global-kb-gap-md, 2rem);max-width:var( --global-content-width, 1200px );padding-left:var(--global-content-edge-padding);padding-right:var(--global-content-edge-padding);padding-top:var(--global-kb-spacing-lg, 3rem);padding-bottom:var(--global-kb-spacing-xl, 4rem);grid-template-columns:minmax(0, 1fr);}.kb-row-layout-id1464_45d497-9e > .kt-row-layout-overlay{opacity:0.30;}@media all and (max-width: 1024px){.kb-row-layout-id1464_45d497-9e > .kt-row-column-wrap{grid-template-columns:minmax(0, 1fr);}}@media all and (max-width: 767px){.kb-row-layout-id1464_45d497-9e > .kt-row-column-wrap{grid-template-columns:minmax(0, 1fr);}}<\/style><div class=\"kb-row-layout-wrap kb-row-layout-id1464_45d497-9e alignfull has-theme-palette6-background-color kt-row-has-bg wp-block-kadence-rowlayout\"><div class=\"kt-row-column-wrap kt-has-1-columns kt-row-layout-equal kt-tab-layout-inherit kt-mobile-layout-row kt-row-valign-top kb-theme-content-width\">\n<style>.kadence-column1464_94c8fc-1e > .kt-inside-inner-col,.kadence-column1464_94c8fc-1e > .kt-inside-inner-col:before{border-top-left-radius:0px;border-top-right-radius:0px;border-bottom-right-radius:0px;border-bottom-left-radius:0px;}.kadence-column1464_94c8fc-1e > .kt-inside-inner-col{column-gap:var(--global-kb-gap-sm, 1rem);}.kadence-column1464_94c8fc-1e > .kt-inside-inner-col{flex-direction:column;}.kadence-column1464_94c8fc-1e > .kt-inside-inner-col > .aligncenter{width:100%;}.kadence-column1464_94c8fc-1e > .kt-inside-inner-col:before{opacity:0.3;}.kadence-column1464_94c8fc-1e{position:relative;}@media all and (max-width: 1024px){.kadence-column1464_94c8fc-1e > .kt-inside-inner-col{flex-direction:column;justify-content:center;}}@media all and (max-width: 767px){.kadence-column1464_94c8fc-1e > .kt-inside-inner-col{flex-direction:column;justify-content:center;}}<\/style>\n<div class=\"wp-block-kadence-column kadence-column1464_94c8fc-1e\"><div class=\"kt-inside-inner-col\">\n<style>\n    \/* Reset and Theme Variables *\/\n    :root {\n      --bg-primary: #02060d;\n      --bg-secondary: #05101a;\n      --bg-tertiary: #0a192f;\n\n      --card-bg: rgba(10, 25, 47, 0.4);\n      --card-border: rgba(255, 94, 0, 0.2);\n      --card-hover-border: rgba(255, 94, 0, 0.8);\n      --card-shadow: 0 8px 32px 0 rgba(0, 0, 0, 0.5);\n\n      --text-primary: #f8fafc;\n      --text-secondary: #cbd5e1;\n      --text-accent: #FF5E00;\n      \/* Bright Orange *\/\n      --text-accent-alt: #FF8C00;\n      \/* Lighter Orange *\/\n      --text-teal: #2dd4bf;\n      \/* Support color *\/\n\n      --gradient-primary: linear-gradient(135deg, #FF5E00 0%, #FF8C00 100%);\n      --glow-color: rgba(255, 94, 0, 0.3);\n    }\n\n    * {\n      box-sizing: border-box;\n      margin: 0;\n      padding: 0;\n    }\n\n    html,\n    body {\n      font-family: 'Inter', sans-serif;\n      background-color: var(--bg-primary);\n      color: var(--text-primary);\n      min-height: 100vh;\n      overflow-x: hidden;\n      line-height: 1.6;\n    }\n\n    \/* Background grids & decorative glows *\/\n    .bg-grid {\n      position: fixed;\n      inset: 0;\n      background-image:\n        linear-gradient(rgba(255, 94, 0, 0.02) 1px, transparent 1px),\n        linear-gradient(90deg, rgba(255, 94, 0, 0.02) 1px, transparent 1px);\n      background-size: 50px 50px;\n      pointer-events: none;\n      z-index: 0;\n    }\n\n    .bg-glow {\n      position: fixed;\n      top: -20%;\n      left: -10%;\n      width: 60vw;\n      height: 60vw;\n      background: radial-gradient(circle, rgba(255, 94, 0, 0.06) 0%, transparent 60%);\n      border-radius: 50%;\n      pointer-events: none;\n      z-index: 0;\n    }\n\n    .bg-glow-2 {\n      position: fixed;\n      bottom: -20%;\n      right: -10%;\n      width: 60vw;\n      height: 60vw;\n      background: radial-gradient(circle, rgba(173, 225, 235, 0.04) 0%, transparent 60%);\n      border-radius: 50%;\n      pointer-events: none;\n      z-index: 0;\n    }\n\n    \/* Layout Wrapper *\/\n    .pipeline-wrapper {\n      position: relative;\n      z-index: 1;\n      padding: 40px 24px 20px;\n      max-width: 1000px;\n      margin: 0 auto;\n    }\n\n    \/* Navigation Back Header *\/\n    .nav-header {\n      margin-bottom: 24px;\n      display: flex;\n      gap: 20px;\n    }\n\n    .back-link {\n      display: inline-flex;\n      align-items: center;\n      gap: 8px;\n      color: var(--text-secondary);\n      text-decoration: none;\n      font-size: 0.9rem;\n      font-weight: 500;\n      transition: color 0.2s ease;\n    }\n\n    .back-link:hover {\n      color: var(--text-accent);\n    }\n\n    .back-link svg {\n      width: 16px;\n      height: 16px;\n      stroke: currentColor;\n      stroke-width: 2;\n      stroke-linecap: round;\n      stroke-linejoin: round;\n      fill: none;\n      transition: transform 0.2s ease;\n    }\n\n    .back-link:hover svg {\n      transform: translateX(-4px);\n    }\n\n    \/* Section Headers *\/\n    .section-header-center {\n      text-align: center;\n      margin-bottom: 28px;\n      max-width: 800px;\n      margin-left: auto;\n      margin-right: auto;\n    }\n\n    .section-title {\n      font-family: 'Outfit', sans-serif;\n      font-size: clamp(1.8rem, 3.5vw, 2.5rem);\n      margin-bottom: 8px;\n      line-height: 1.2;\n      font-weight: 800;\n      letter-spacing: -0.02em;\n    }\n\n    .section-subtitle {\n      font-size: 1.05rem;\n      color: var(--text-secondary);\n    }\n\n    .gradient-text {\n      background: var(--gradient-primary);\n      -webkit-background-clip: text;\n      -webkit-text-fill-color: transparent;\n      background-clip: text;\n      color: transparent;\n      display: inline-block;\n    }\n\n    \/* Assets List Container *\/\n    .assets-container {\n      display: flex;\n      flex-direction: column;\n      gap: 16px;\n      width: 100%;\n    }\n\n    \/* Glassmorphic Asset Card *\/\n    .asset-card {\n      background: var(--card-bg);\n      backdrop-filter: blur(16px);\n      -webkit-backdrop-filter: blur(16px);\n      border: 1px solid var(--card-border);\n      border-left: 4px solid var(--text-accent-alt);\n      border-radius: 16px;\n      padding: 20px 28px;\n      box-shadow: var(--card-shadow);\n      transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1);\n    }\n\n    .asset-card:hover {\n      border-left-color: var(--text-accent);\n      background: rgba(10, 25, 47, 0.65);\n      box-shadow: 0 12px 40px rgba(255, 94, 0, 0.15);\n      transform: translateY(-2px);\n    }\n\n    .asset-header {\n      display: flex;\n      justify-content: flex-start;\n      align-items: center;\n      margin-bottom: 16px;\n      cursor: pointer;\n      user-select: none;\n      gap: 12px;\n    }\n\n    .asset-title-group {\n      display: flex;\n      flex-direction: row;\n      align-items: center;\n      gap: 12px;\n    }\n\n    \/* Translucent Badge style *\/\n    .asset-badge {\n      display: inline-block;\n      background: rgba(255, 94, 0, 0.12);\n      color: var(--text-accent-alt);\n      border: 1px solid rgba(255, 94, 0, 0.2);\n      padding: 2px 10px;\n      border-radius: 20px;\n      font-size: 0.75rem;\n      font-weight: 700;\n      text-transform: uppercase;\n      letter-spacing: 1px;\n    }\n\n    .asset-title {\n      font-family: 'Outfit', sans-serif;\n      font-size: 1.35rem;\n      color: var(--text-primary);\n      margin: 0;\n      font-weight: 700;\n      letter-spacing: -0.01em;\n    }\n\n    \/* Collapsible Details Container *\/\n    .details-wrapper {\n      display: grid;\n      grid-template-rows: 0fr;\n      transition: grid-template-rows 0.4s cubic-bezier(0.25, 0.8, 0.25, 1);\n    }\n\n    .details-wrapper.expanded {\n      grid-template-rows: 1fr;\n    }\n\n    .details-content {\n      overflow: hidden;\n      display: flex;\n      flex-direction: column;\n    }\n\n    \/* Target Indications (styled as original Collaboration element capsule) *\/\n    .asset-indications {\n      align-self: flex-start;\n      display: inline-block;\n      background: rgba(255, 255, 255, 0.05);\n      border: 1px solid rgba(255, 255, 255, 0.03);\n      padding: 8px 16px;\n      border-radius: 8px;\n      font-size: 0.95rem;\n      color: var(--text-primary);\n      margin-bottom: 20px;\n      line-height: 1.5;\n    }\n\n    .asset-indications strong {\n      color: var(--text-teal);\n      font-weight: 700;\n      margin-right: 6px;\n    }\n\n    \/* Multi-paragraph descriptions *\/\n    .asset-desc-group {\n      display: flex;\n      flex-direction: column;\n      gap: 12px;\n      margin-bottom: 20px;\n      padding-top: 10px;\n    }\n\n    .asset-desc {\n      font-size: 0.95rem;\n      color: var(--text-secondary);\n      line-height: 1.6;\n    }\n\n    \/* Toggle Button Chevron *\/\n    .toggle-btn {\n      background: none;\n      border: none;\n      outline: none;\n      cursor: pointer;\n      width: 32px;\n      height: 32px;\n      border-radius: 50%;\n      display: flex;\n      align-items: center;\n      justify-content: center;\n      background: rgba(255, 255, 255, 0.04);\n      border: 1px solid rgba(255, 255, 255, 0.08);\n      transition: all 0.3s ease;\n      flex-shrink: 0;\n    }\n\n    .toggle-btn svg {\n      width: 16px;\n      height: 16px;\n      stroke: var(--text-secondary);\n      stroke-width: 2.5;\n      stroke-linecap: round;\n      stroke-linejoin: round;\n      fill: none;\n      transition: transform 0.3s cubic-bezier(0.25, 0.8, 0.25, 1);\n    }\n\n    .asset-card:hover .toggle-btn {\n      border-color: rgba(255, 94, 0, 0.3);\n      background: rgba(255, 94, 0, 0.1);\n    }\n\n    .asset-card:hover .toggle-btn svg {\n      stroke: var(--text-accent);\n    }\n\n    .toggle-btn.rotated svg {\n      transform: rotate(180deg);\n    }\n\n    \/* Phase Tracker container *\/\n    .asset-tracker-container {\n      padding-top: 16px;\n    }\n\n    .phase-tracker {\n      display: flex;\n      justify-content: space-between;\n      position: relative;\n    }\n\n    \/* Gray tracker pipeline line *\/\n    .phase-tracker::before {\n      content: '';\n      position: absolute;\n      top: 6px;\n      left: 0;\n      width: 100%;\n      height: 2px;\n      background: rgba(255, 255, 255, 0.08);\n      z-index: 1;\n    }\n\n    .tracker-step {\n      display: flex;\n      flex-direction: column;\n      align-items: center;\n      position: relative;\n      z-index: 2;\n      flex: 1;\n    }\n\n    .tracker-dot {\n      width: 14px;\n      height: 14px;\n      border-radius: 50%;\n      background: var(--bg-tertiary);\n      border: 2px solid rgba(255, 255, 255, 0.2);\n      margin-bottom: 6px;\n      transition: all 0.3s ease;\n    }\n\n    .tracker-label {\n      font-size: 0.8rem;\n      color: var(--text-secondary);\n      font-weight: 500;\n      text-align: center;\n      transition: all 0.3s ease;\n    }\n\n    \/* Completed state formatting *\/\n    .tracker-step.completed .tracker-dot {\n      background: var(--text-accent);\n      border-color: var(--text-accent);\n    }\n\n    .tracker-step.completed .tracker-label {\n      color: var(--text-primary);\n    }\n\n    \/* Active\/Glow state formatting *\/\n    .tracker-step.active .tracker-dot {\n      background: var(--bg-primary);\n      border-color: var(--text-accent);\n      box-shadow: 0 0 10px rgba(255, 94, 0, 0.5);\n      transform: scale(1.15);\n    }\n\n    .tracker-step.active .tracker-label {\n      color: var(--text-accent);\n      font-weight: 700;\n    }\n\n    \/* Active connecting line segments *\/\n    .tracker-step.completed::after {\n      content: '';\n      position: absolute;\n      top: 6px;\n      left: 50%;\n      width: 100%;\n      height: 2px;\n      background: var(--text-accent);\n      z-index: -1;\n    }\n\n    .tracker-step:last-child::after {\n      display: none;\n    }\n\n    \/* Mobile Responsive formatting for Timeline *\/\n    @media (max-width: 768px) {\n      .asset-card {\n        padding: 16px 20px;\n      }\n\n      .asset-title-group {\n        flex-direction: column;\n        align-items: flex-start;\n        gap: 6px;\n      }\n\n      .asset-title {\n        font-size: 1.15rem;\n      }\n\n      .asset-badge {\n        font-size: 0.65rem;\n        padding: 1px 8px;\n      }\n\n      .phase-tracker {\n        flex-direction: column;\n        gap: 12px;\n        align-items: flex-start;\n      }\n\n      .phase-tracker::before {\n        left: 6px;\n        top: 0;\n        width: 2px;\n        height: 100%;\n      }\n\n      .tracker-step {\n        flex-direction: row;\n        gap: 12px;\n        width: 100%;\n        align-items: center;\n      }\n\n      .tracker-dot {\n        margin-bottom: 0;\n      }\n\n      .tracker-step.completed::after {\n        left: 6px;\n        top: 14px;\n        width: 2px;\n        height: calc(100% + 12px);\n      }\n    }\n  <\/style>\n\n<!-- Main Section Header -->\n    <div class=\"section-header-center\">\n      <h2 class=\"section-title\">Therapeutic <span class=\"gradient-text\">Programs<\/span><\/h2>\n    <\/div>\n\n    <!-- Assets List -->\n    <main class=\"assets-container\">\n\n      <!-- Asset 1: 9B02 Anti-PD-L1 -->\n      <article class=\"asset-card\">\n        <div class=\"asset-header\">\n          <span class=\"toggle-btn\" role=\"button\" aria-label=\"Toggle details\" style=\"display: inline-flex !important; align-items: center !important; justify-content: center !important; width: 32px !important; height: 32px !important; min-width: 32px !important; min-height: 32px !important; max-width: 32px !important; max-height: 32px !important; border-radius: 50% !important; box-sizing: border-box !important; padding: 0 !important; margin: 0 !important; cursor: pointer !important; flex-shrink: 0 !important; line-height: 1 !important; background: rgba(255, 255, 255, 0.04); border: 1px solid rgba(255, 255, 255, 0.08); color: #cbd5e1;\">\n            <svg viewBox=\"0 0 24 24\" width=\"16\" height=\"16\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\" stroke-linecap=\"round\" stroke-linejoin=\"round\" style=\"width: 16px !important; height: 16px !important; display: block !important; transition: transform 0.3s cubic-bezier(0.25, 0.8, 0.25, 1) !important;\">\n              <polyline points=\"6 9 12 15 18 9\"><\/polyline>\n            <\/svg>\n          <\/span>\n          <div class=\"asset-title-group\">\n            <h3 class=\"asset-title\">9B02: Anti-PD-L1<\/h3>\n            <span class=\"asset-badge\">Monoclonal ADC<\/span>\n          <\/div>\n        <\/div>\n\n        <div class=\"details-wrapper\">\n          <div class=\"details-content\">\n            <div class=\"asset-desc-group\">\n              <p class=\"asset-desc\">\n                9B02 is a conditional, tumor-selective anti-PD-L1 ADC designed to address key limitations of current\n                PD-1\/PD-L1 therapies. By preferentially binding PD-L1 within the tumor microenvironment, 9B02 is\n                designed to improve tumor selectivity and patient tolerability.\n              <\/p>\n              <p class=\"asset-desc\">\n                It enables direct elimination of both\n                PD-L1-positive tumor cells and immunosuppressive tumor-resident immune cells, offering a differentiated\n                mechanism beyond checkpoint inhibition and potential benefit in patients with compromised immune\n                function following chemotherapy or radiation.\n              <\/p>\n              <p class=\"asset-desc\">\n                Its conditional binding profile is also being leveraged in next-generation bispecifics to improve the safety of challenging tumor targets through avidity-driven tumor-selective binding. 9Bio is open to collaborations that advance differentiated bi- or multispecific therapeutics using our conditional anti-PD-L1 antibodies.\n              <\/p>\n            <\/div>\n\n            <div class=\"asset-indications\">\n              <strong>Indications:<\/strong> Gastric and bladder cancers, with broader potential across\n              non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), head and neck cancer (HNC), and\n              melanoma.\n            <\/div>\n          <\/div>\n        <\/div>\n\n        <div class=\"asset-tracker-container\">\n          <div class=\"phase-tracker\">\n            <div class=\"tracker-step completed\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Target Selection<\/span>\n            <\/div>\n            <div class=\"tracker-step completed\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Lead Discovery<\/span>\n            <\/div>\n            <div class=\"tracker-step completed\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Lead Optimization<\/span>\n            <\/div>\n            <div class=\"tracker-step active\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Preclinical<\/span>\n            <\/div>\n            <div class=\"tracker-step\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">IND Enabling<\/span>\n            <\/div>\n            <div class=\"tracker-step\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Phase 1<\/span>\n            <\/div>\n          <\/div>\n        <\/div>\n      <\/article>\n\n      <!-- Asset 2: 9B05 Undisclosed target -->\n      <article class=\"asset-card\">\n        <div class=\"asset-header\">\n          <span class=\"toggle-btn\" role=\"button\" aria-label=\"Toggle details\" style=\"display: inline-flex !important; align-items: center !important; justify-content: center !important; width: 32px !important; height: 32px !important; min-width: 32px !important; min-height: 32px !important; max-width: 32px !important; max-height: 32px !important; border-radius: 50% !important; box-sizing: border-box !important; padding: 0 !important; margin: 0 !important; cursor: pointer !important; flex-shrink: 0 !important; line-height: 1 !important; background: rgba(255, 255, 255, 0.04); border: 1px solid rgba(255, 255, 255, 0.08); color: #cbd5e1;\">\n            <svg viewBox=\"0 0 24 24\" width=\"16\" height=\"16\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\" stroke-linecap=\"round\" stroke-linejoin=\"round\" style=\"width: 16px !important; height: 16px !important; display: block !important; transition: transform 0.3s cubic-bezier(0.25, 0.8, 0.25, 1) !important;\">\n              <polyline points=\"6 9 12 15 18 9\"><\/polyline>\n            <\/svg>\n          <\/span>\n          <div class=\"asset-title-group\">\n            <h3 class=\"asset-title\">9B05: Undisclosed target<\/h3>\n            <span class=\"asset-badge\">Bispecific ADC<\/span>\n          <\/div>\n        <\/div>\n\n        <div class=\"details-wrapper\">\n          <div class=\"details-content\">\n            <div class=\"asset-desc-group\">\n              <p class=\"asset-desc\">\n                9B05 is a bispecific ADC for the treatment of patients with advanced metastatic cancers.  It combines a clinically validated tumor antigen associated with cancer stemness, chemotherapy resistance, and metastasis, supported by prior Phase 1 evidence of anti-tumor activity, with a second novel tumor antigen associated with metastatic progression in colorectal, gastric, and breast cancers. \n              <\/p>\n              <p class=\"asset-desc\">\n                The program is currently in lead characterization and optimization in the bispecific format and is being\n                advanced for late-stage, particularly metastatic breast, colorectal, gastric, and liver cancers.\n              <\/p>\n            <\/div>\n\n            <div class=\"asset-indications\">\n              <strong>Indications:<\/strong> Breast, colorectal, gastric, and liver metastatic disease.\n            <\/div>\n          <\/div>\n        <\/div>\n\n        <div class=\"asset-tracker-container\">\n          <div class=\"phase-tracker\">\n            <div class=\"tracker-step completed\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Target Selection<\/span>\n            <\/div>\n            <div class=\"tracker-step completed\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Lead Discovery<\/span>\n            <\/div>\n            <div class=\"tracker-step active\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Lead Optimization<\/span>\n            <\/div>\n            <div class=\"tracker-step\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Preclinical<\/span>\n            <\/div>\n            <div class=\"tracker-step\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">IND Enabling<\/span>\n            <\/div>\n            <div class=\"tracker-step\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Phase 1<\/span>\n            <\/div>\n          <\/div>\n        <\/div>\n      <\/article>\n\n      <!-- Asset 3: 9B06 Undisclosed target -->\n      <article class=\"asset-card\">\n        <div class=\"asset-header\">\n          <span class=\"toggle-btn\" role=\"button\" aria-label=\"Toggle details\" style=\"display: inline-flex !important; align-items: center !important; justify-content: center !important; width: 32px !important; height: 32px !important; min-width: 32px !important; min-height: 32px !important; max-width: 32px !important; max-height: 32px !important; border-radius: 50% !important; box-sizing: border-box !important; padding: 0 !important; margin: 0 !important; cursor: pointer !important; flex-shrink: 0 !important; line-height: 1 !important; background: rgba(255, 255, 255, 0.04); border: 1px solid rgba(255, 255, 255, 0.08); color: #cbd5e1;\">\n            <svg viewBox=\"0 0 24 24\" width=\"16\" height=\"16\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\" stroke-linecap=\"round\" stroke-linejoin=\"round\" style=\"width: 16px !important; height: 16px !important; display: block !important; transition: transform 0.3s cubic-bezier(0.25, 0.8, 0.25, 1) !important;\">\n              <polyline points=\"6 9 12 15 18 9\"><\/polyline>\n            <\/svg>\n          <\/span>\n          <div class=\"asset-title-group\">\n            <h3 class=\"asset-title\">9B06: Undisclosed target<\/h3>\n            <span class=\"asset-badge\">Bispecific ADC<\/span>\n          <\/div>\n        <\/div>\n\n        <div class=\"details-wrapper\">\n          <div class=\"details-content\">\n            <div class=\"asset-desc-group\">\n              <p class=\"asset-desc\">\n                9B06 is a next-generation bispecific ADC that combines 9Bio\u2019s conditional, tumor-selective anti-PD-L1\n                ADC platform with a complementary tumor-associated antigen linked to aggressive and metastatic disease.\n              <\/p>\n              <p class=\"asset-desc\">\n                By pairing conditional PD-L1 targeting with a second tumor-localizing arm, 9B06 is designed to improve\n                tumor selectivity through avidity-driven binding while enabling direct cytotoxic activity against both\n                PD-L1-positive tumor cells and immunosuppressive cells within the tumor microenvironment.\n              <\/p>\n              <p class=\"asset-desc\">\n                This approach is intended to extend the potential of 9B02 beyond single-target PD-L1 biology and support\n                treatment of advanced tumors where immune suppression, metastatic progression, and heterogeneous target\n                expression limit current therapeutic options.\n              <\/p>\n            <\/div>\n\n            <div class=\"asset-indications\">\n              <strong>Indications:<\/strong> Advanced and metastatic solid tumors, with initial focus on cancers\n              where PD-L1 expression and metastatic biology contribute to disease progression.\n            <\/div>\n          <\/div>\n        <\/div>\n\n        <div class=\"asset-tracker-container\">\n          <div class=\"phase-tracker\">\n            <div class=\"tracker-step completed\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Target Selection<\/span>\n            <\/div>\n            <div class=\"tracker-step completed\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Lead Discovery<\/span>\n            <\/div>\n            <div class=\"tracker-step active\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Lead Optimization<\/span>\n            <\/div>\n            <div class=\"tracker-step\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Preclinical<\/span>\n            <\/div>\n            <div class=\"tracker-step\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">IND Enabling<\/span>\n            <\/div>\n            <div class=\"tracker-step\">\n              <div class=\"tracker-dot\"><\/div>\n              <span class=\"tracker-label\">Phase 1<\/span>\n            <\/div>\n          <\/div>\n        <\/div>\n      <\/article>\n\n    <\/main>\n  \n\n  <script>\n    \/\/ Handle toggle details collapse\/expand\n    document.querySelectorAll('.asset-card').forEach(card => {\n      const header = card.querySelector('.asset-header');\n      const wrapper = card.querySelector('.details-wrapper');\n      const btn = card.querySelector('.toggle-btn');\n\n      header.addEventListener('click', () => {\n        wrapper.classList.toggle('expanded');\n        btn.classList.toggle('rotated');\n      });\n    });\n  <\/script>\n<\/div><\/div>\n\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Pipeline Conditionally active precision oncology therapeutics Our pipeline directly&nbsp;validates&nbsp;the capabilities of our computational platform and is guided by two core&nbsp;objectives.&nbsp; First, we use our platform to reduce off-tumor target engagement&#8230;<\/p>","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-1464","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pipeline - 9Bio Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/9biotx.com\/fr\/pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pipeline - 9Bio Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Pipeline Conditionally active precision oncology therapeutics Our pipeline directly&nbsp;validates&nbsp;the capabilities of our computational platform and is guided by two core&nbsp;objectives.&nbsp; First, we use our platform to reduce off-tumor target engagement...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/9biotx.com\/fr\/pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"9Bio Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T21:57:44+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/pipeline\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/pipeline\\\/\",\"name\":\"Pipeline - 9Bio Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\"},\"datePublished\":\"2023-08-25T15:04:15+00:00\",\"dateModified\":\"2026-06-01T21:57:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/pipeline\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/9biotx.com\\\/pipeline\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/9biotx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"name\":\"9Bio Therapeutics\",\"description\":\"Engineering Biological Possibilities\",\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/9biotx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\",\"name\":\"9Bio Therapeutics\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"contentUrl\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"width\":200,\"height\":80,\"caption\":\"9Bio Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/9bio\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pipeline - 9Bio Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/9biotx.com\/fr\/pipeline\/","og_locale":"fr_CA","og_type":"article","og_title":"Pipeline - 9Bio Therapeutics","og_description":"Pipeline Conditionally active precision oncology therapeutics Our pipeline directly&nbsp;validates&nbsp;the capabilities of our computational platform and is guided by two core&nbsp;objectives.&nbsp; First, we use our platform to reduce off-tumor target engagement...","og_url":"https:\/\/9biotx.com\/fr\/pipeline\/","og_site_name":"9Bio Therapeutics","article_modified_time":"2026-06-01T21:57:44+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/9biotx.com\/pipeline\/","url":"https:\/\/9biotx.com\/pipeline\/","name":"Pipeline - 9Bio Therapeutics","isPartOf":{"@id":"https:\/\/9biotx.com\/#website"},"datePublished":"2023-08-25T15:04:15+00:00","dateModified":"2026-06-01T21:57:44+00:00","breadcrumb":{"@id":"https:\/\/9biotx.com\/pipeline\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/9biotx.com\/pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/9biotx.com\/pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/9biotx.com\/"},{"@type":"ListItem","position":2,"name":"Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/9biotx.com\/#website","url":"https:\/\/9biotx.com\/","name":"9Bio Th\u00e9rapeutiques","description":"Engineering Biological Possibilities","publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/9biotx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/9biotx.com\/#organization","name":"9Bio Th\u00e9rapeutiques","url":"https:\/\/9biotx.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/","url":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","contentUrl":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","width":200,"height":80,"caption":"9Bio Therapeutics"},"image":{"@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/9bio\/"]}]}},"taxonomy_info":[],"featured_image_src_large":false,"author_info":{"display_name":"Henrique de Carvalho","author_link":"https:\/\/9biotx.com\/fr\/news\/author\/decarvalho\/"},"comment_info":0,"_links":{"self":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/pages\/1464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/comments?post=1464"}],"version-history":[{"count":48,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/pages\/1464\/revisions"}],"predecessor-version":[{"id":2421,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/pages\/1464\/revisions\/2421"}],"wp:attachment":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/media?parent=1464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}